Navigation Links
Peloton Therapeutics Completes $18 Million Series A Financing
Date:7/27/2011

DALLAS, July 27, 2011 /PRNewswire/ -- Peloton Therapeutics, Inc., an early-stage cancer drug discovery and development company, has announced the completion of an $18 million Series A financing.  Led by The Column Group and joined by Remeditex Ventures and Peter O'Donnell, Jr., the Series A funds supplement a recently awarded $11 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

Peloton officials said the company will focus initially on advancing several well differentiated oncology programs, each of which has already yielded promising lead compounds with novel mechanisms of action. Peloton leveraged its close relationship with the University of Texas Southwestern Medical Center to in-license these programs, providing a kick-start to its internal research and development capabilities. Peloton's goal is to become a leading oncology company generating a sustainable pipeline of cancer therapies that are designed to enhance outcomes and treatment practices.  

The Company was founded by renowned scientist Steven L. McKnight, Ph.D., who is recognized as one of the world leaders in gene regulation based in part on his discovery of leucine zipper proteins. Dr. McKnight is Chairman of Biochemistry at UT Southwestern and holds the Distinguished Chair in Basic Biomedical Research and the Sam G. Winstead and F. Andrew Bell Distinguished Chair in Biochemistry. The high-throughput screening laboratory Dr. McKnight built at the medical center over the past decade has seeded the Peloton pipeline with a number of attractive compounds that are well positioned for lead optimization.

"Peloton has the potential to emerge as a top-notch cancer company, distinguished by its scientific rigor, drug discovery capabilities, and talented team," Dr. McKnight said. "Peloton is off to a strong start in advancing its therapeutic programs quickly and effectively."

Peloton's Board of Directors includes Nobel Laureate Michael S.
'/>"/>

SOURCE Peloton Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
2. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
3. Oxygen Healthcare (O2h) Announces Expanded Chemistry Collaboration With Heptares Therapeutics
4. Dr. Andrew Scharenberg, M.D., to Serve as Chief Scientific Officer for Cellectis therapeutics
5. Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe
6. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
7. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
8. Sorrento Therapeutics Innovative Approach to Developing Vaccines and Therapeutics for MRSA Receives Continued Support From the National Institute of Allergy and Infectious Diseases
9. Amicus Therapeutics Joins Russell 3000® Index
10. Nile Therapeutics Provides Update on Ongoing Phase I Clinical Trial of Cenderitide
11. Nile Therapeutics, Inc. Completes $2.5 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Oregon , July 29, 2014 ... "Global surgical equipment market (types, applications and geography) - ... Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020", ... to reach $12.1 billion by 2020 registering a CAGR ... to the breakthrough achieved by the electro surgical devices ...
(Date:7/29/2014)... Hershey, PA & Rockville, MD (PRWEB) July 29, ... Immunomic Therapeutics, Inc. (ITI), a vaccine pioneer in ... the financial services firm Newport Coast Securities, Inc. ... , ITI is commercializing LAMP-vax technology, a breakthrough ... $25B+ vaccines and immunotherapy market. The company exclusively ...
(Date:7/29/2014)... Hill, South Carolina (PRWEB) July 29, 2014 ... with teams of people where cell phone masts or other ... iPhones up to 100 feet away without the need for ... to target longer ranges. , The new app has launched ... of US homes are at very high risk of being ...
(Date:7/29/2014)... 29, 2014 The first product launch ... generation approach to robotics. What sets Droidles completely apart ... technology that allows them to communicate, share code with ... the internet. , “The invention is the system,” said ... Droidles a life of their own, both physically and ...
Breaking Biology Technology:Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 3Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3DisasterTalk App Could Save Lives as Report Reveals 8% of US Homes at Very High Risk of Natural Disaster 2Droidles, the Social Network of Robots and Open Source Platform for the Internet of Things, Launches for Crowd Funding on IndieGoGo.com 2
... , DURHAM, N.C., Aug. 12 Oxygen Biotherapeutics, Inc. (OTC Bulletin ... 10-K for the fiscal year ended April 30, 2009. In addition to being available ... v , the 10-K can be downloaded from the company website at ... the Investors page. , , For the year ended April 30, ...
... , , LYNBROOK, N.Y., Aug. 12 ... company developing first in class collagenase-based products, today announced its ... , , "We were very pleased ... with Priority Review for XIAFLEX(TM) for the treatment of Dupuytren,s ...
... , , SAN DIEGO, Aug. 12 ... results for the three and six months ended June 30, 2009. , ... have the capital to complete and submit a New Drug Application (NDA) ... said Brian M. Culley, Principal Executive Officer at ADVENTRX. "Our financial ...
Cached Biology Technology:Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009 2Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009 3BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 5BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 6ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 2ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 3ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 4ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 5ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 6ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 7
(Date:7/29/2014)... affects 1 in 100,000 people characterized by a loss ... remains unknown, a new study by a team of researchers ... Germany and other European institutions confirms for the first time ... 6 July in Nature Genetics , is an important ... a sphincter in the lower esophagus opens, allowing food to ...
(Date:7/29/2014)... UC San Francisco is the first to show that ... accelerate cellular aging, these negative effects may be reduced ... , "The study participants who exercised, slept well ... ones who didn,t maintain healthy lifestyles, even when they ... Puterman, PhD, assistant professor in the department of psychiatry ...
(Date:7/28/2014)... discovery of two additional coral communities showing signs of damage ... of the 2010 spill in the Gulf of Mexico. The ... professor of biology at Penn State University. A paper describing ... in the Gulf of Mexico will be published during the ... of the journal Proceedings of the National Academy of ...
Breaking Biology News(10 mins):Mysterious esophagus disease is autoimmune after all 2Healthy lifestyle may buffer against stress-related cell aging, study says 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2
... it may be more lyrical than useful when discussing ... of the Sackler Institute of Comparative Genomics at the ... the University of Colorado at Boulder. The team used ... the populations of small mammals living on mountaintops in ...
... on a nano scale how can you see what you ... Biological Sciences research Council (BBSRC) fellow has made a significant ... With new research published today (13 August) in ... School of Pharmacy (University of London) and the University of ...
... also available in German . Halle/Saale, ... plant species could lose parts of its current range, ... Environmental Research (UFZ), the Potsdam Institute for Climate Impact ... Species distributions will be rearranged as a result of ...
Cached Biology News:Sky islands: metaphor or misnomer? 2Scientists overcome nanotech hurdle 2Scientists overcome nanotech hurdle 3Climate change threatens 1 in 5 plant species 2
Prepared in distilled water....
... RiboGreen RNA Quantitation Kit is one ... for the quantitation of RNA in ... 1000-fold more sensitive than absorbance measurements. ... be detected with fluorescence microplate readers ...
Request Info...
Recommend to use at up to 5000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
Biology Products: